Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cahaba Research

Neither a doctor nor a teaching hospital

Research payments

$6,623,563

159 payments

Through program year 2025, Cahaba Research is reported as receiving $6,623,563 in research payments, across 159 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,224,190 20
2024 Research $1,805,132 46
2023 Research $1,809,741 36
2022 Research $329,519 7
2021 Research $830,989 31
2020 Research $581,565 12
2019 Research $42,427 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $6,233,685 92 payments
  2. OraSure Technologies Inc. $180,847 9 payments
  3. Genentech, Inc. $171,135 36 payments
  4. AbbVie, Inc. $37,897 22 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $1,116,273 4 payments
  2. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $1,077,057 7 payments
  3. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $931,345 4 payments
  4. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $898,164 9 payments
  5. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $560,941 5 payments
  6. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $532,057 4 payments
  7. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $254,141 4 payments
  8. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 Administered Weekly Using A Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naive Adults With Type 2 Diabetes $186,022 2 payments
  9. A Multicenter Study Conducted to Evaluate the Performance of the COVID-19 Self-Test $180,847 9 payments
  10. Transmission Study Household $171,135 36 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record